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Lenalidomide is a potent immunomodulatory agent that has
demonstrated clinical activity in the treatment of both dif-
fuse large B cell lymphomas (DLBCL) and mantle cell
lymphomas (MCL). In relapsed/refractory (R/R) DLBCL,
two large prospective studies evaluating lenalidomide
monotherapy demonstrated an overall response rate (ORR)
of 28% (N= 108) and 27.5% (N= 51), respectively [1, 2].
In patients with R/R MCL patients, lenalidomide induced an
ORR of 40% (N= 170) [3, 4]. In 2013, the FDA approved
lenalidomide for the treatment of R/R MCL.
Obinutuzumab is a unique type II glycoengineered
monoclonal anti-CD20 antibody (Ab) with increased
ADCC and increased direct cell death induction compared
to rituximab. In monotherapy, obinutuzumab demonstrated
efﬁcacy in patients with MCL and DLBCL [5]. The ORR
after treatment with obinutuzumab monotherapy was 28%
and 27% in R/R DLBCL and MCL, respectively [5].
Furthermore, the combination of lenalidomide and
rituximab (R2 regimen) demonstrated promising efﬁcacy in
patients with follicular lymphoma (FL) [6, 7], MCL [8, 9],
and DLBCL [10–13]. We hypothesized that the combina-
tion of obinutuzumab (GA) with lenalidomide (LEN) might
be even more efﬁcient while retaining a good safety proﬁle.
In a phase IB study, we previously identiﬁed 20 mg/day
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as the recommended dose (RD) of lenalidomide in combi-
nation with obinutuzumab for the induction phase [14]. In
this phase II study, we assessed the efﬁcacy and safety of
the combination of obinutuzumab with lenalidomide
(GALEN) for patients with R/R aggressive lymphoma (i.e.,
DLBCL and MCL). Patient eligibility, study design, and
statistical analysis are summarized in Supplementary
Information and Supplementary Figure 1.
From June 2014 to March 2015, 91 patients were enrolled
and 85 patients were assessable for the GALEN combination.
Median age for the entire cohort was 70 years (range 48–84).
The median number of prior therapies was 2 (1–9). Sixty-
eight percent of the patients were refractory to rituximab and/
or to the last line of therapy. The patient population was
composed of 71 DLBCL and 13 MCL. One patient had an
aggressive lymphoma which was unclassiﬁed. Baseline
characteristics of the patients at enrollment are listed in
Supplementary Table 1. Overall, 39 patients (45.9%) com-
pleted induction (32 DLBCL and 7 MCL) and 17 pts (20.0%)
completed maintenance (13 DLBCL, 4 MCL) (Supplemen-
tary Figure 2). After a median follow-up of 2.5 years, 50 pts
(58.8%) died, mainly due to lymphoma (88%).
For the entire cohort (N= 85), the ORR at the end of
induction treatment by IWG criteria [15] was 36.5% (95%
CI, 26.3–47.6) (Supplementary Table 2A). Thus, the pri-
mary endpoint of the study was not met (cf Statistical
Analysis in Supplementary Information).
In DLBCL patients (N= 71), the ORR and CR/CRu at
the end of induction treatment by IWG criteria (Cheson
1999) was 35.2% (95% CI, 24.2–47.5) and 18.3% (95% CI,
10.1–29.3), respectively (Fig. 1 and Supplementary
Table 2A). Median PFS and OS were 4.1 months and
10.6 months, respectively (Fig. 2 and Supplementary
Table 2A). Outcome of DLBCL patients was also analyzed
according the cell of origin (COO) as determined by
immunohistochemistry (IHC) using the Hans algorithm and
by gene expression proﬁle (GEP) using the nanostring and
the RT-MLPA technologies. The two GEP methods were
concordant and complementary for determining the COO
(Supplementary Table 4). Overall response, PFS and OS
tended to be better in the ABC versus the GCB-subtype,
although the differences were not statistically signiﬁcant
(Supplementary Table 2B and Supplementary Figure 3).
There was no difference in efﬁcacy between de novo versus
transformed DLBCL nor according to cereblon expression
or the number of prior treatments (data not shown). Finally,
refractory patients (N= 38) as deﬁned by the SCHOLAR-I
study [16] (i.e., absence of response to the last treatment or
Fig. 1 Tumor regression at the end of induction
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relapse within 12 months from autologous stem cell trans-
plantation) had a signiﬁcantly worse outcome compared to
non-refractory patients (N= 33) with an ORR of 13.2% and
a median OS of 6.6 months (Supplementary Table 2C and
Supplementary Figure 4). Conversely, among non-
refractory DLBCL, the ORR was 60.6% including 33.3%
CR, the median PFS was 11.7 months, and the median OS
was not reached. The largest study evaluating the R2 regi-
men (N= 45) in R/R DLBCL reported an ORR of 33%,
including 22% CR, a median PFS of 3.7 months and a
median OS of 10.7 months [12]. While these results appear
similar to ours, both studies cannot be compared directly.
Notably, the proportion of refractory patients (not described
in the study of Wang et al.) was particularly high in our
study (up to 70% of the patients) which negatively affected
the results of efﬁcacy. The GOYA study did not demon-
strate superiority of obinutuzumab over rituximab in com-
bination with ﬁrst-line chemotherapy [17]. However, one
should be careful not to extrapolate these results to chemo-
free regimen since the mechanism of action (including the
synergy with lenalidomide) may be different. Czuczman
et al. previously demonstrated that lenalidomide mono-
therapy was more efﬁcient in the ABC-subtype compared to
the GCB-subtype of DLBCL [1]. With the GALEN regi-
men, the same trend was observed and this combination
seemed to overcome the negative prognostic impact of non-
germinal center DLBCL. When applying the GALEN
regimen in refractory DLBCL, the outcome remained poor
with a median OS of 6.6 months. These results are similar to
those described with standard chemotherapy in the
SCHOLAR-I study in which the median OS was
6.3 months [16]. Nevertheless, although the OR rate with
the GALEN regimen was low in this population (13.2%),
some patients experienced prolonged remissions with a
median duration of response of 20.2 months (Supplemen-
tary Table 2C and Supplementary Figure 4).
In MCL patients (N= 13), the ORR and CR/CRu at the
end of induction treatment by IWG criteria (Cheson 1999)
was 46.2% (95% CI, 19.2–74.9) and 15.4% (95% CI, 1.9–
45.5), respectively (Fig. 1 and Supplementary Table 2A).
With a median follow-up of 2.5 years, median PFS and OS
were 5.8 months and not reached, respectively (Fig. 2 and
Supplementary Table 2A). Trněný et al. demonstrated that
lenalidomide monotherapy induced an ORR of 40%
(N= 170) including 5% of CR/CRu in R/R MCL (MCL-002/
SPRINT trial) [3]. With a median follow-up of 15.9 months,
the median PFS was 8.7 months. Another study, conducted by
Wang et al., evaluated the combination of lenalidomide and
rituximab in R/R MCL patients (N= 44 at the recommended
dose) [8]. The ORR was 57% including 36% of CR. With a
median follow-up of 23.1 months, the median PFS was
11.1 months. In our study, the results appear inferior (OR=
46.2%, CR/CRu= 15.4%, median PFS= 5.8 months).
However, the number of MCL patients in our study is limited
(N= 13). Furthermore, most of our patients were refractory or
had relapsed after intensive therapy, suggesting that their
disease might have been more severe or resistant. Indeed,
A Duraon of response
B Progression-free survival
C Overall survival
Fig. 2 Duration of response (a), progression-free survival (b), and
overall survival (c) according to histology (DLBCL and MCL)
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53.8% of our patients had received prior ASCT versus 13% in
the study by Wang et al.
The safety population included 88 patients who received
at least one drug. The most common and severe (≥grade 3)
adverse events occurring during induction are reported in
Supplementary Table 3. The most frequent toxicities con-
sisted in neutropenia (54.5%), fatigue (36.4%), constipation
(31.8%), and diarrhea (26.1%). Other AEs of interest
included rash (9.1%), febrile neutropenia (4.5%), infusion-
related reactions (4.5%), tumor ﬂare reactions (4.5%), and
tumor lysis syndrome (1.1%). Three patients (3.4%)
experienced venous thrombosis despite systematic prophy-
laxis. The most severe toxicities (≥grade 3) consisted in
neutropenia (50.0%), thrombocytopenia (13.6%), and ane-
mia (10.2%). Finally, four patients developed second pri-
mary malignancies (SPM) consisting in one acute myeloid
leukemia (which occurred 8 months after the end of
GALEN study treatment in a patient who had received six
prior lines of chemotherapy), one basal cell carcinoma, one
myelodysplastic syndrome (which occurred 6 months after
GALEN discontinuation and 4 months after an autologous
stem cell transplantation in a patient who had received three
prior lines of chemotherapy) and one stomach adenocarci-
noma. Overall, 26 (29.5%) patients had a dose reduction of
lenalidomide because of toxicity and 4 (4.5%) patients
prematurely and permanently discontinued the treatment
because of toxicity. Six patients died during GALEN
treatment: four due to lymphoma and two from concurrent
illness (inﬂuenza respiratory infection and hemorrhage,
respectively). There was no unexpected toxicity based on
the known side effects of obinutuzumab and lenalidomide.
In the largest study evaluating the R2 regimen in R/R
DLBCL (N= 45) [12], the most common grade 3-4 adverse
events were neutropenia (53%), thrombocytopenia (33%),
anemia (18%). There were few grade 3–4 non-
hematological events. These side effects are comparable
to the ones observed with the GALEN regimen.
Overall, the chemo-free GALEN regimen is effective and
well tolerated in R/R patients with aggressive lymphoma.
Thus, the GALEN regimen may represent an option in
DLBCL patients with R/R disease after two lines of con-
ventional chemotherapy, especially in ABC-DLBCL.
Whether this regimen may be superior to the R2 regimen
(rituximab-lenalidomide) remains to be determined.
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Somatic driver mutations in exon 9 of the calreticulin
(CALR) gene were ﬁrst identiﬁed in 2013 [1], with a
reported mutational frequency of 15–25% in essential
thrombocythemia (ET) [2] and 25–35% in primary myelo-
ﬁbrosis (PMF) [3]. Over 80% of these mutations constitute
variants deﬁned as either type 1, a 52 bp deletion (p.
L367fs*46), or type 2, a 5 bp TTGTC insertion (p.
K385fs*47) [1]. Subsequent reports have exposed these
mutants’ differential distribution according to disease sub-
type [4] in addition to their phenotypic and prognostic
disparities in both ET and PMF [5, 6]. Importantly, type 1
CALR variants, which comprise ~70% of all CALR muta-
tions in PMF [1], have emerged as a phenotypically and
prognostically distinct mutational subset, clustering with
lower dynamic international prognostic scoring system
(DIPSS)-plus scores and signiﬁcantly favorable survival
rates compared with both CALR type 2 and JAK2 mutated
cohorts [5, 7, 8]. Moreover, molecular interactions between
CALR type 1 and additional genetic lesions such as ASXL1
are of proven prognostic relevance [9]. Despite these
advances however, little is known about the natural history
of CALR type 1-mutated PMF. Firstly, independent clinical,
cytogenetic, and molecular predictors of survival have not
yet been appraised in a strictly CALR type 1-mutated PMF
population. Furthermore, it is not clear whether long-term
survival in this strictly molecularly deﬁned subgroup can be
reliably assessed using contemporary prognostic models.
The current study comprehensively documents the mole-
cular correlates and determinants of long-term outcome, as
measured by overall (OS), leukemia-free (LFS), and
* Ayalew Tefferi
tefferi.ayalew@mayo.edu
1 Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
2 Divisions of Hematopathology, Mayo Clinic, Rochester, MN,
USA
3 Laboratory Genetics and Genomics, Departments of Internal and
Laboratory Medicine, Mayo Clinic, Rochester, MN, USA
780 Brief Communication
